Cerecor Inc. (CERC)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cerecor Inc. (CERC) trades at $2.93 with AI Score 50/100 (Grade B). Cerecor Inc. is a biopharmaceutical company focused on developing treatments for rare pediatric and orphan diseases. Market cap: $38.63M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for CERC: CERC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CERC against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
CERC: the 1 perspectives are evenly split.
How is this calculated? →Cerecor Inc. (CERC) Healthcare & Pipeline Overview
Cerecor Inc. is a biopharmaceutical company specializing in the development and commercialization of treatments for rare pediatric and orphan diseases. With a focus on inherited metabolic disorders and autoimmune inflammatory diseases, Cerecor aims to address unmet medical needs in niche patient populations within the biotechnology sector.
What Is the Investment Thesis for CERC?
Cerecor Inc. presents a high-risk, high-reward investment opportunity within the biopharmaceutical sector. The company's focus on rare pediatric and orphan diseases offers the potential for significant revenue generation upon successful drug approval and commercialization, given the typically higher pricing power for orphan drugs. A key value driver is the advancement of its pipeline assets, particularly CERC-007 and CERC-913, through clinical trials. Upcoming catalysts include clinical trial readouts and potential FDA approvals. However, the company's small market capitalization of $38.63M and limited resources pose significant risks, including potential funding challenges and clinical trial failures. The company's high profit margin of 37444.5% and gross margin of 64.1% are notable, but these metrics may be volatile given the nature of the biotechnology industry.
Based on FMP financials and quantitative analysis
CERC Key Highlights
- Market Cap of $38.63M reflects its small size within the biotechnology industry.
- Profit Margin of 37444.5% indicates potential profitability, but may be unsustainable due to R&D expenses.
- Gross Margin of 64.1% suggests strong pricing power for its commercialized product, Millipred.
- Beta of 1.44 indicates higher volatility compared to the overall market.
- Focus on rare pediatric and orphan diseases offers potential for accelerated regulatory pathways and market exclusivity.
Who Are CERC's Competitors?
CERC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| TLX Telix Pharmaceuticals Limited | $12.15 | +2.36% | $4.12B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CERC's Key Strengths?
- Focus on rare pediatric and orphan diseases.
- Proprietary pipeline of novel drug candidates.
- Commercialized product (Millipred) generating revenue.
- Experienced management team.
What Are CERC's Weaknesses?
- Small market capitalization and limited financial resources.
- Dependence on successful clinical trial outcomes.
- High R&D expenses.
- Limited commercial infrastructure.
What Could Drive CERC Stock Higher?
- Clinical trial readouts for CERC-007 in autoimmune inflammatory diseases.
- Clinical trial readouts for CERC-913 in mitochondrial disorders.
- Potential FDA approval for pipeline assets.
- Strategic partnerships with larger pharmaceutical companies.
What Are the Key Risks for CERC?
- Financial-distress signal — its Altman Z-Score of -6.89 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures.
- Regulatory hurdles.
- Competition from other pharmaceutical companies.
- Patent challenges.
- Limited financial resources.
What Are the Growth Opportunities for CERC?
- Advancement of CERC-007: CERC-007, an anti-IL-18 monoclonal antibody, targets autoimmune inflammatory diseases. The market for autoimmune disease treatments is substantial, estimated at billions of dollars annually. Successful clinical trials and subsequent FDA approval could generate significant revenue. The timeline for potential approval is dependent on clinical trial progress, but could be within the next 3-5 years. Cerecor's competitive advantage lies in the novelty of targeting IL-18.
- Development of CERC-913: CERC-913, a protide nucleotide, is being developed for the treatment of mitochondrial disorders. Mitochondrial disorders represent a significant unmet medical need, with limited treatment options available. Successful development and commercialization of CERC-913 could capture a substantial portion of this market. The timeline for potential approval is dependent on clinical trial progress, but could be within the next 5-7 years.
- Expansion of Millipred Sales: Millipred, an oral prednisolone, is already commercialized and generates revenue for Cerecor. Expanding the sales and marketing efforts for Millipred could drive additional revenue growth. The market for prednisolone is well-established, but Cerecor could differentiate Millipred through targeted marketing and distribution strategies. This growth opportunity could be realized within the next 1-2 years.
- Strategic Partnerships: Cerecor could pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its pipeline assets. Such partnerships could provide Cerecor with additional funding and expertise, while also validating its technology. The timeline for potential partnerships is uncertain, but could occur at any point in the development process.
- Acquisition of Complementary Assets: Cerecor could acquire complementary assets, such as other drug candidates or technologies, to expand its pipeline and diversify its revenue streams. This could involve acquiring assets from other small biotech companies or licensing technologies from academic institutions. The timeline for potential acquisitions is uncertain, but could occur as Cerecor generates additional revenue and funding.
What Opportunities Does CERC Have?
- Advancement of pipeline assets through clinical trials.
- Strategic partnerships with larger pharmaceutical companies.
- Acquisition of complementary assets.
- Expansion of Millipred sales.
What Threats Does CERC Face?
- Clinical trial failures.
- Regulatory hurdles.
- Competition from other pharmaceutical companies.
- Patent challenges.
What Are CERC's Competitive Advantages?
- Focus on rare diseases provides potential for market exclusivity and pricing power.
- Proprietary pipeline of novel drug candidates.
- Intellectual property protection for its drug candidates.
- Expertise in developing and commercializing treatments for rare diseases.
What Does CERC Do?
Cerecor Inc., founded in 2011 and headquartered in Rockville, Maryland, is a biopharmaceutical company dedicated to the development and commercialization of treatments for rare pediatric and orphan diseases. Originally named Ceregen Corporation, the company rebranded in March 2011 to reflect its evolving focus. Cerecor's pipeline includes therapies targeting inherited metabolic disorders, such as CERC-801, CERC-802, and CERC-803, all of which are in various stages of clinical development. The company is also developing CERC-007, an anti-IL-18 monoclonal antibody for autoimmune inflammatory diseases like adult-onset stills disease and multiple myeloma; CERC-006, a dual mTOR inhibitor for complex lymphatic malformations; and CERC-002, an anti-LIGHT monoclonal antibody for Pediatric-onset Crohn's diseases. Further, Cerecor is advancing CERC-913, a protide nucleotide for mitochondrial disorders; CERC-005, a monoclonal antibody for rare auto-inflammatory diseases; CERC-301 for symptomatic Orthostatic Hypotension; and CERC-406 for Parkinson's disease. In addition to its pipeline, Cerecor offers Millipred, an oral prednisolone used to treat inflammatory conditions.
What Products and Services Does CERC Offer?
- Develop therapies for inherited metabolic disorders.
- Develop monoclonal antibodies for autoimmune inflammatory diseases.
- Develop treatments for complex lymphatic malformations.
- Develop treatments for Pediatric-onset Crohn's diseases.
- Develop treatments for mitochondrial disorders.
- Offer Millipred, an oral prednisolone for inflammatory conditions.
How Does CERC Make Money?
- Develop and commercialize treatments for rare pediatric and orphan diseases.
- Generate revenue through the sale of Millipred.
- Out-license or partner for further development and commercialization of pipeline assets.
- Receive funding through grants, venture capital, and public offerings.
What Industry Does CERC Operate In?
Cerecor Inc. operates within the biotechnology industry, which is characterized by high R&D spending, long development timelines, and significant regulatory hurdles. The market for orphan drugs is growing, driven by increased awareness and regulatory incentives such as the Orphan Drug Act. Competition is intense, with both large pharmaceutical companies and smaller biotechs vying for market share. Cerecor's focus on rare diseases positions it within a niche segment, potentially offering a competitive advantage in terms of market exclusivity and pricing power. The biotechnology industry is expected to continue growing, driven by technological advancements and increasing demand for novel therapies.
Who Are CERC's Key Customers?
- Patients with rare pediatric and orphan diseases.
- Hospitals and clinics that treat these patients.
- Pharmacies that dispense medications.
- Payers, including insurance companies and government healthcare programs.
How Cerecor Inc. Is Valued
Cerecor Inc. carries a market capitalization of $38.63M, placing it in the micro-cap category. Relative to its peer group, CERC's quantitative score of 50/100 is below the peer average of 76/100.
Company Profile
Cerecor Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Rockville, US. The company is led by CEO Michael Cola. CERC has traded publicly since 2015.
Key Financial Metrics
Return on assets is -98.0%, showing how much profit it generates from its asset base. A current ratio of 7.66 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -166.2%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 1/9Financial Health
Cerecor Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -6.89 places it in the distress zone, a signal of elevated financial risk.
Net buyingInsider Activity
The most recent 12 insider filings for Cerecor Inc. break down as 0 sales and 12 purchases. On net that is roughly 284K shares acquired (about $952K) — insiders putting money in tends to read as conviction.
CERC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Cerecor's recent strategic shift towards rare pediatric diseases is gaining traction within the community, suggesting a focused and potentially lucrative market. This is reminiscent of how companies focusing on niche markets, like some biotech firms specializing in orphan drugs, can attract investor interest.
- Insider activity shows recent purchases, hinting at internal confidence in the company's direction. While not a guarantee, it mirrors situations where management believes the market undervalues their company.
- Community sentiment reflects optimism around upcoming clinical trial results, with many anticipating positive outcomes. This is similar to the buzz surrounding potential blockbuster drug announcements in the pharmaceutical sector.
- The market is starting to perceive Cerecor as a potential acquisition target due to its specialized pipeline, creating speculative buying pressure. This is akin to situations where smaller companies with promising technologies are bought by larger players.
Bear Case
- The company's history of strategic pivots raises concerns about long-term vision and execution. This is similar to companies that frequently change direction, leading to investor skepticism.
- Social media sentiment reveals doubts about the company's ability to successfully navigate the regulatory landscape for rare disease treatments. This echoes concerns faced by many smaller biotechs trying to bring novel therapies to market.
- Despite positive sentiment regarding clinical trials, there's underlying apprehension about potential setbacks or delays. This is a common fear in the biotech industry, where clinical trial outcomes are uncertain.
- Community discussions highlight concerns about the company's cash burn rate and potential need for future dilutive financing. This is a typical worry for smaller biotech companies that are pre-revenue.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CERC Latest News
No recent news available for CERC.
CERC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CERC.
Price Targets
Wall Street price target analysis for CERC.
CERC MoonshotScore
What does this score mean?
The MoonshotScore rates CERC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Michael Cola
CEO
Michael Cola serves as the CEO of Cerecor Inc., managing a team of 30 employees. Information about his detailed career history, education, and previous roles is not available. His leadership is focused on guiding Cerecor's strategic direction and overseeing the development and commercialization of treatments for rare pediatric and orphan diseases.
Track Record: Specific achievements, strategic decisions, and company milestones under Michael Cola's leadership are not available. His focus is on advancing Cerecor's pipeline and navigating the regulatory landscape.
Cerecor Inc. Healthcare Stock: Key Questions Answered
What does Cerecor Inc. do?
Cerecor Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for rare pediatric and orphan diseases. The company's pipeline includes therapies targeting inherited metabolic disorders, autoimmune inflammatory diseases, and mitochondrial disorders. Cerecor also markets Millipred, an oral prednisolone for inflammatory conditions. The company aims to address unmet medical needs in niche patient populations through innovative drug development.
What do analysts say about CERC stock?
Analyst coverage of CERC stock is Unknown. Key valuation metrics and growth considerations are also Unknown. Investors should conduct their own due diligence and consider the risks and uncertainties associated with investing in a small-cap biotechnology company focused on rare diseases. The company's financial performance and clinical trial outcomes will be critical factors in determining its future success.
What are the main risks for CERC?
The main risks for Cerecor Inc. include clinical trial failures, regulatory hurdles, competition from other pharmaceutical companies, patent challenges, and limited financial resources. Clinical trial failures could significantly impact the company's pipeline and future revenue potential. Regulatory hurdles could delay or prevent the approval of its drug candidates. Competition from larger pharmaceutical companies with greater resources could limit its market share. Patent challenges could jeopardize its intellectual property protection. Limited financial resources could constrain its ability to fund its R&D efforts.
What are the key factors to evaluate for CERC?
Cerecor Inc. (CERC) holds an AI score of 50/100 (moderate). Not financial advice.
How frequently does CERC data refresh on this page?
CERC prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CERC's recent stock price performance?
Cerecor Inc. (CERC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on rare pediatric and orphan diseases. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CERC overvalued or undervalued right now?
Valuing Cerecor Inc. (CERC) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CERC?
Before investing in Cerecor Inc. (CERC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Analyst ratings and financial data may not be current.
- Investment in biotechnology companies is inherently risky.